ReviewOncology reports2025
SENP1: A perspective from immune cells to disease (Review).
Review in Oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small ubiquitin‑like modifier (SUMO) is a ubiquitin‑like protein that modifies target proteins across various eukaryotic subcellular structures. This process, known as SUMOylation, has been established as an essential regulatory mechanism that affects both the activity and positioning of proteins, maintaining cellular homeostasis. SUMOylation and deSUMOylation are reversible post‑translational modification processes mediated by SUMO proteins and SUMO/sentrin‑specific proteases (SENPs). The human SENP family comprises six members, each characterized by unique cellular localization and substrate specificity. The present review primarily summarizes the role and mechanisms of SENP1 in the development and maturation of immune cells, including lymphocytes, macrophages and erythrocytes, as well as its involvement in tumor cell invasion, metastasis, angiogenesis and resistance to pharmacological therapies. In addition, the introduction of SENP1 inhibitors as a therapeutic approach for cancer treatment is explored. Overall, the present study aimed to offer theoretical insights into cancer therapy strategies that target SENP1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.